BrainStorm Cell Therapeutics GAAP EPS of -$0.04 in-line

2024-08-14 19:34

BrainStorm Cell Therapeutics press release (NASDAQ:BCLI): Q2 GAAP EPS of -$0.04 in-line.
Cash, cash equivalents, and restricted cash amounted to approximately $3.65 million, as of June 30, 2024.

More on BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
IPO Roundup: Actuate Therapeutics, Autozi Internet, and more
BrainStorm Cell Therapeutics announces pricing of $4M registered direct offering
Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
Historical earnings data for BrainStorm Cell Therapeutics